Depomed, Inc. (DEPO) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 19 PAGES: 45

More Info
									         Depomed, Inc. (DEPO) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH28808FSA                                                                                          Publication Date: MAR 2013

          7999 Gateway Boulevard, Suite 300                  Phone              +1 510 7448000                  Revenue          90.8 (million USD)
          Newark, CA                                         Fax                +1 510 7448001                  Net Profit       -29.78 (million USD)
          94560                                              Website            www.depomed.com                 Employees        267
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           DEPO [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Depomed, Inc. (Depomed) is a specialty pharmaceutical company. It focuses on the development and commercialization of drugs
       indicated for the treatment of pain and other diseases of the central nervous system, type 2 diabetes, menopausal hot flashes
       and Parkinson's disease. The company's product portfolio comprises Gralise, administered to treat postherpetic neuralgia caused
       by viral infection, herpes zoster, or nerve damage; Zipsor, indicated for the treatment of mild to moderate acute pain in adults;
       and Glumetza, a once-daily treatment for adults with type 2 diabetes.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Depomed, Inc., SWOT Analysis
         James A. Schoeneck                  Chief Executive Officer                  Strengths                              Weaknesses
         G. Steven Burrill                   Director
                                                                                      Advanced Technological Base Narrow Supplier Base
         Karen A. Dawes                      Director
                                                                                      Focused Research and                   SEFELSA
         Peter D. Staple                     Director
                                                                                      Development Initiative
         David B. Zenoff                     Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Strategic Agreements                   Uncertain Research and
         Depomed, Inc.                                                                                                       Development Outcomes
                                                                                      Market Potential – CNS
        Share Price (USD) as on 15-Mar-                                  5.68         Therapy                                Increase in Competitive
        2013                                                                                                                 Pressure
        EPS (USD)                                                       -0.53
        Market Cap (million USD)                                         321         Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        Enterprise Value (million USD)                                   243
        Shares Outstanding (million)                                       56
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 20, 2013         Depomed Reports Revenue Of $26.6m In Q4
                                                                                                           2012
                                                                                      Nov 05, 2012         Depomed Reports Revenue Of $33.3m In Q3
                                                                                                           2012
                                                                                      Oct 02, 2012         Depomed Completes Conversion Of Contract
                                                                                                           Sales Force To Direct Employees
                                                                                      Aug 02, 2012         Depomed Reports Revenue Of $14.1m In Q2
                                                                                                           2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Depomed, Inc. (DEPO) - Financial and Strategic SWOT Analysis                                                                   Reference Code: GDPH28808FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Depomed, Inc. - Key Facts ................................................................................................................................................................. 5
       Depomed, Inc. - Key Employees ........................................................................................................................................................ 6
       Depomed, Inc. - Key Employee Biographies ...................................................................................................................................... 7
       Depomed, Inc. - Major Products and Services ................................................................................................................................... 8
       Depomed, Inc. - Pharmaceutical Pipeline Products Data ................................................................................................................... 9
          Depomed, Inc., Pipeline Products by Therapy Area ....................................................................................................................... 9
          Depomed, Inc., Pipeline Products by Development Phase ........................................................................................................... 10
       Depomed, Inc. - History .................................................................................................................................................................... 12
       Depomed, Inc. - Company Statement .............................................................................................................................................. 16
       Depomed, Inc. - Locations And Subsidiaries .................................................................................................................................... 21
          Head Office ................................................................................................................................................................................... 21
       Section 2 – Company Analysis ......................................................................................................................................................... 22
       Depomed, Inc. - Business Description ............................................................................................................................................. 22
       Depomed, Inc. - Corporate Strategy................................................................................................................................................. 23
       Depomed, Inc. - SWOT Analysis ...................................................................................................................................................... 24
          SWOT Analysis - Overview........................................................................................................................................................... 24
          Depomed, Inc. - Strengths ............................................................................................................................................................ 24
             Strength - Advanced Technological Base ................................................................................................................................. 24
             Strength - Focused Research and Development Initiative ........................................................................................................ 24
             Strength - License Agreements ................................................................................................................................................. 24
          Depomed, Inc. - Weaknesses ....................................................................................................................................................... 25
             Weakness - Narrow Supplier Base............................................................................................................................................ 25
             Weakness - SEFELSA .............................................................................................................................................................. 25
          Depomed, Inc. - Opportunities ...................................................................................................................................................... 25
             Opportunity - Strategic Agreements .......................................................................................................................................... 25
             Opportunity - Market Potential – CNS Therapy ......................................................................................................................... 25
             Opportunity - Robust Product Pipeline ...................................................................................................................................... 26
          Depomed, Inc. - Threats ............................................................................................................................................................... 26
             Threat - Uncertain Research and Development Outcomes ....................................................................................................... 26
             Threat - Increase in Competitive Pressure ................................................................................................................................ 26
             Threat - Government Regulations ............................................................................................................................................. 26
       Depomed, Inc. - Key Competitors .................................................................................................................................................... 28
       Section 3 – Company Financial Ratios ............................................................................................................................................. 29
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 29
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 29
       Performance Chart ........................................................................................................................................................................... 31
       Financial Performance...................................................................................................................................................................... 31
       Financial Ratios - Interim Ratios....................................................................................................................................................... 32
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 33
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 34
          Depomed, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013..................................................................... 34


Depomed, Inc. (DEPO) - Financial and Strategic SWOT Analysis                                                                                                   Reference Code: GDPH28808FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Depomed, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 .................................................................... 35
       Depomed, Inc., Recent Deals Summary .......................................................................................................................................... 36
       Section 5 – Company’s Recent Developments ................................................................................................................................ 37
          Depomed, Inc., Recent Developments .......................................................................
								
To top